To disclose, or not to disclose? Perspectives of clinical genomics professionals toward returning incidental findings from genomic research

• Published in: BMC medical ethics Vol. 22; no. 1; pp. 1 - 101
• Main Authors: AlFayyad, Isamme, Al-Tannir, Mohamad, Abu-Shaheen, Amani, AlGhamdi, Saleh
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 27-07-2021; BioMed Central; BMC
• Subjects: Attitudes; Barriers; Bioethics; Disclosure; Disclosure of information; Empowerment; Ethical aspects; Genetic research; Genomic research; Genomics; Incidental findings; Medical ethics; Medical research; Patients; Perception; Public opinion; Questionnaires; Saudi Arabia
• ISSN: 1472-6939; 1472-6939
• DOI: 10.1186/s12910-021-00670-y

Clinical genomic professionals are increasingly facing decisions about returning incidental findings (IFs) from genetic research. Although previous studies have shown that research participants are interested in receiving IFs, yet there has been an argument about the extent of researcher obligation to return IFs. We aimed in this study to explore the perspectives of clinical genomics professionals toward returning incidental findings from genomic research. We conducted a national survey of a sample (n = 113) of clinical genomic professionals using a convenient sampling. A self-administered questionnaire was used to explore their attitudes toward disclosure of IFs, their perception of the duties to return IFs and identifying the barriers for disclosure of IFs. A descriptive analysis was employed to describe participants' responses. Sixty-five (57.5%) respondents had faced IFs in their practice and 31 (27.4%) were not comfortable in discussing IFs with their research subjects. Less than one-third of the respondents reported the availability of guidelines governing IFs. The majority 84 (80%) and 69 (62.7%) of the study participants indicated they would return the IFs if the risk of disease threat [greater than or equai to] 50% and 6-49%, respectively and 36 (31.9%) reported they have no obligation to return IFs. Clinical genomics professionals have positive attitudes and perceptions toward the returning IFs from genomic research, yet some revealed no duty to do so. Detailed guidelines must be established to provide insights into how genomics professionals should be handled IFs.